PALOMA Study Launches to Explore Oculometric Biomarkers in Parkinson’s Disease

NeuraLight has launched the PALOMA (Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson’s Disease) study — a multicenter, longitudinal clinical trial designed to explore how oculometric measures relate to established clinical assessments in Parkinson’s disease (PD).

Registered as NCT05862649 on ClinicalTrials.gov, the study is being conducted at several international sites, including Rush University (Chicago, USA), the AIBILI Research Center (Coimbra, Portugal), the Instituto de Biomedicina de Sevilla (IBiS) (Seville, Spain) and Oxford network sites (United Kingdom).

PALOMA will enroll approximately 300 participants diagnosed with idiopathic Parkinson’s disease within the past five years. Over a 12-month period, participants will complete regular visits that include standard neurological and cognitive assessments and oculometric evaluations conducted using the NeuraLight platfrom.

The study aims to determine how changes in eye movement patterns correlate with clinical measures of disease severity and progression and seeks to advance understanding of how eye movement biomarkers can provide objective, sensitive measures of Parkinson’s disease progression.

This study represents another milestone in NeuraLight’s mission to transform neurological research and care through precise, AI-driven biomarkers.